Solid Biosciences LLC (SLDB) — Cash Flow-to-Debt Ratio
Solid Biosciences LLC (SLDB) has a Cash Flow-to-Debt Ratio of -0.60x as of September 2025, meaning its operating cash flow of $-33.47 Million could theoretically repay -1% of its total liabilities ($55.97 Million) in one year. See Solid Biosciences LLC (SLDB) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Solid Biosciences LLC Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Solid Biosciences LLC across 10 annual periods. Also explore Solid Biosciences LLC (SLDB) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Solid Biosciences LLC (2015–2024)
Year-by-year debt coverage analysis for Solid Biosciences LLC. For market capitalisation and broader financial context, see SLDB stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.95x | $-100.01 Million | $51.42 Million | ▲ +20.6% |
| 2023 | -2.45x | $-94.18 Million | $38.46 Million | ▼ -21.4% |
| 2022 | -2.02x | $-97.98 Million | $48.59 Million | ▲ +37.3% |
| 2021 | -3.22x | $-77.76 Million | $24.17 Million | ▼ -122.2% |
| 2020 | -1.45x | $-56.60 Million | $39.08 Million | ▲ +63.4% |
| 2019 | -3.96x | $-92.71 Million | $23.42 Million | ▲ +18.7% |
| 2018 | -4.87x | $-70.20 Million | $14.41 Million | ▼ -1426.1% |
| 2017 | -0.32x | $-43.22 Million | $135.45 Million | ▼ -24.5% |
| 2016 | -0.26x | $-20.12 Million | $78.52 Million | ▼ -360.9% |
| 2015 | -0.06x | $-4.20 Million | $75.62 Million | — |